Answers are grounded in this paper and cite their sources.
Performance evaluation of NicCheck I test strips for nicotine metabolites in urine indicates reliability, suggesting enhanced patient compliance.
Background Smoking is recognized as a risk factor for adverse postoperative outcomes following a variety of surgical procedures. Patients opting for elective aesthetic surgery are advised to abstain from smoking prior to surgery. To assess compliance, many plastic surgeons have started testing patients for tobacco consumption on the day of surgery using point-of-care screening methods. NicCheck I from Mossman Associates (Milford, MA) is an FDA cleared, CLIA waived rapid urine test that provides a semi-quantitative assessment of nicotine and/or its metabolites. Objective: To evaluate the performance of NicCheck I test strips to detect nicotine and its metabolites in urine samples. Methods Frozen urine samples (n=24) were obtained from ARUP laboratories (Salt Lake City, UT). These included negative (n=12) samples for cotinine verified by Enzyme Multiplied Immunoassay technique and positive (n=12) samples for nicotine and metabolites verified by Quantitative Liquid Chromatography-Tandem Mass spectrometry (LC-MS/MS) respectively. NicCheck I positive/negative cotinine controls and urine samples were tested using the NicCheck I test strips following manufacturer’s protocol. Sample pH and integrity were assessed on Clinitek status analyzer using Siemens Multistix 10 SG reagent strips (Tarrytown, NY). Results NicCheck I test strips for the cotinine negative urine samples (n=12) did not develop any color after 15 minutes, indicating absence of nicotine and/or metabolites. NicCheck I strips incubated with LC-MS/MS confirmed positive urine samples developed a pink color in 9 out of the 12 samples indicating the presence of nicotine and/or metabolites. NicCheck I test strips can detect cotinine >200 ng/mL with a positive predictive value of 98.4% and two of the samples that tested false negative with the NicCheck I strips had lower amounts (cotinine 32 ng/mL and 17 ng/mL and nicotine and metabolites of <102 ng/mL and <83 ng/mL respectively) of total nicotine metabolites compared to other samples as measured by LC-MS/MS which has a lower cutoff concentration for detection of nicotine and metabolites at 85 ng/mL (nicotine 15ng/mL, cotinine 15 ng/mL, 3-OH-cotinine 50 ng/mL and anabasine 5 ng/mL). Color development on the strip for one of the positive samples which had a pH of 9 (assay’s optimal pH range is 4.5-8.5), was not uniform despite having high levels of nicotine and its metabolites (cotinine 1063 ng/mL; nicotine and metabolites >3156 ng/mL). Conclusion NicCheck I test strips perform sufficiently for screening urine samples for the presence of nicotine and/or its metabolites. However, the NicCheck I test is less sensitive than LC-MS/MS and urine samples close to the LC-MS/MS cutoff concentration as well as samples outside of pH 4.5 – 8.5 may show false negativity as noted from this small study. Rapid point of care screening modalities to assess patients’ smoking status prior to elective surgeries could aid in decision making for surgeons, increase patient compliance, and possibly improve post-surgical outcomes.
No takes yet. Share an insight, caveat, or question.
Bhandari et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: